newsfilter
← Latest News
Business Wire·

Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results

- Zimura® GATHER2 Topline Data Expected in September of this Year- - GATHER2 Patient Retention Continues to Exceed Expectations with a 12-Month Injection Fidelity Rate of 92.5% – - Agreement for up to $250 Million in Non-dilutive Debt Financing